http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-108148050-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07B2200-07 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-12 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4178 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D403-12 |
| filingDate | 2018-01-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2019-09-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2019-09-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-108148050-B |
| titleOfInvention | A kind of active medicine and application thereof for treatment of human cervical cancer |
| abstract | The present invention relates to the active medicine midpacamide or (S)-midpacamide for treatment of human cervical cancer.Research shows that, midpacamide has very strong inhibiting effect for cervical cancer cell Hela, the inhibitory activity of two stereoisomers has significant difference, and (S)-midpacamide is for 50 times or more that the inhibitory activity of cervical cancer cell Hela is (R)-midpacamide.Furthermore, compared with the midpacamide of prior art report is to the inhibiting effect of mouse lymphoma cell L5178Y, midpacamide and (S)-midpacamide is for 10000 times or more that the inhibitory activity of cervical cancer cell Hela is to mouse lymphoma cell L5178Y.As it can be seen that midpacamide and (S)-midpacamide has special, efficient therapeutic activity for cervical carcinoma. |
| priorityDate | 2018-01-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 58.